Christopher Cubitt
YOU?
Author Swipe
View article: Pembrolizumab plus High-Dose IL-2 in Advanced Clear Cell Renal Cell Carcinoma: Six-Year Survival Outcomes and Molecular Signatures from a Phase 2 Trial
Pembrolizumab plus High-Dose IL-2 in Advanced Clear Cell Renal Cell Carcinoma: Six-Year Survival Outcomes and Molecular Signatures from a Phase 2 Trial Open
Prolonged or indefinite systemic therapy remains standard for advanced clear cell renal cell carcinoma (ccRCC), often resulting in cumulative toxicities and treatment burden. We conducted a single-arm phase 2 trial of a fixed-duration regi…
View article: Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients
Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients Open
Background: Immunocompromised populations, especially cancer patients, rely on the effectiveness of the COVID-19 vaccines to protect against severe infection or death, both against the original wild-type (WT) SARS CoV-2 virus and its many …
View article: Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma Open
We demonstrate that carcinogenesis and multi-therapy resistance in multiple myeloma (MM)—a treatable yet incurable plasma cell malignancy—are driven by epigenetic dysregulation. In this new paradigm, genomic and cytogenetic events unlock e…
View article: CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease
CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease Open
PURPOSE This phase I-Ib trial evaluated a novel CD40L blocking antibody, BMS-986004, for the prevention of graft-versus-host disease (GVHD) after unrelated donor allogeneic hematopoietic cell transplantation (HCT). PATIENTS AND METHODS A t…
View article: Data from The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma
Data from The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma Open
Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow–resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes. In this study, w…
View article: Supplementary Data from The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma
Supplementary Data from The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma Open
This file contains four supplementary tables S1 - S4 and eight supplementary figures S1 - S8.
View article: The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma Open
Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow–resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes. In this study, w…
View article: Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients Open
Cancer patients are at an increased risk of morbidity and mortality from SARS-CoV-2 infection and have a decreased immune response to vaccination. We conducted a study measuring both the neutralizing and total antibodies in cancer patients…
View article: Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients Open
Background Compared to the general population, cancer patients are at higher risk of morbidity and mortality following SARS‐CoV‐2 infection. The immune response to a two‐dose regimen of mRNA vaccines in cancer patients is generally lower t…
View article: Data from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma
Data from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma Open
Multiple myeloma remains treatable but incurable. Despite a growing armamentarium of effective agents, choice of therapy, especially in relapse, still relies almost exclusively on clinical acumen. We have developed a system, Ex vivo Mathem…
View article: Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia Open
Supplementary table and figures.
View article: Supplementary Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
Supplementary Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma Open
Supplemental figures
View article: Supplemental Figures and Tables from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma
Supplemental Figures and Tables from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma Open
Supplemental Figures and Tables to augment (1) the mathematical modeling (providing details on specific therapeutics); (2) patient characteristics (treatment history, clinical and predicted response), (3) synergistic activities identified …
View article: Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia Open
Supplementary table and figures.
View article: Supplemental Figure 6 from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma
Supplemental Figure 6 from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma Open
Individual patient EMMA predicitons of actual responses to therapy (companion to Figure 3i).
View article: Data from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma
Data from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma Open
Multiple myeloma remains treatable but incurable. Despite a growing armamentarium of effective agents, choice of therapy, especially in relapse, still relies almost exclusively on clinical acumen. We have developed a system, Ex vivo Mathem…
View article: Supplemental Figures and Tables from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma
Supplemental Figures and Tables from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma Open
Supplemental Figures and Tables to augment (1) the mathematical modeling (providing details on specific therapeutics); (2) patient characteristics (treatment history, clinical and predicted response), (3) synergistic activities identified …
View article: Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma Open
High-dose chemotherapy with melphalan followed by autologous transplantation is a first-line treatment for multiple myeloma. Here, we present preclinical evidence that this treatment may be significantly improved by the addition of exporti…
View article: Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia Open
Supplementary Methods.
View article: Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia Open
Purpose:Induction chemotherapy results in complete remission (CR) rates of 20% to 50% among patients with poor-risk AML. Selinexor is an oral selective inhibitor of nuclear export with promising single-agent activity. By inhibiting the pri…
View article: Supplemental Figure 6 from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma
Supplemental Figure 6 from An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple Myeloma Open
Individual patient EMMA predicitons of actual responses to therapy (companion to Figure 3i).
View article: Supplementary Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
Supplementary Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma Open
Supplemental figures
View article: Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia Open
Purpose:Induction chemotherapy results in complete remission (CR) rates of 20% to 50% among patients with poor-risk AML. Selinexor is an oral selective inhibitor of nuclear export with promising single-agent activity. By inhibiting the pri…
View article: Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma Open
High-dose chemotherapy with melphalan followed by autologous transplantation is a first-line treatment for multiple myeloma. Here, we present preclinical evidence that this treatment may be significantly improved by the addition of exporti…
View article: Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia Open
Supplementary Methods.
View article: Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML) Open
The pathologic process in traumatic brain injury marked by delayed axonal loss, known as diffuse axonal injury (DAI), leads to partial deafferentation of neurons downstream of injured axons. This process is linked to persistent visual dysf…
View article: Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study
Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study Open
We conducted a prospective study to evaluate immune responses to SARS-CoV-2 in oncology workers in which we collected blood and clinical data every 6 months. Spike-specific CD4+ T-cells and immunoglobulin G responses were measured using in…
View article: Functional transcriptomic landscape informs novel therapeutic strategies in multiple myeloma
Functional transcriptomic landscape informs novel therapeutic strategies in multiple myeloma Open
We present a unique database of tumor samples from 399 multiple myeloma (MM) patients, whose functional genomic landscape was assessed by integrating ex vivo drug sensitivity to 138 drugs, clinical variables, cytogenetics, mutational profi…